Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21447257 | 1.00 | LMNA (0.49) | LMNAMAPTSMN1; SMN2OPRM1CCR2 | |
| SCHEMBL23375794 | 1.00 | LMNA (0.49) | LMNAMAPTSMN1; SMN2OPRM1CCR2 | |
| SCHEMBL21447253 | 1.00 | LMNA (0.49) | LMNAMAPTSMN1; SMN2OPRM1CCR2 | |
| SCHEMBL21438851 | 1.00 | LMNA (0.49) | LMNAMAPTSMN1; SMN2OPRM1CCR2 | |
| SCHEMBL23356985 | 1.00 | LMNA (0.49) | LMNAMAPTSMN1; SMN2OPRM1CCR2 | |
| SCHEMBL21447252 | 1.00 | LMNA (0.49) | LMNAMAPTSMN1; SMN2OPRM1CCR2 | |
| SCHEMBL23375803 | 1.00 | LMNA (0.49) | LMNAMAPTSMN1; SMN2OPRM1CCR2 | |
| SCHEMBL6156393 | 0.86 | LMNA (0.51) | LMNAMAPTSMN1; SMN2OPRM1CCR2 | |
| SCHEMBL6156395 | 0.86 | LMNA (0.51) | LMNAMAPTSMN1; SMN2OPRM1CCR2 | |
| SCHEMBL29221489 | 0.85 | CCR2 (0.46) | LMNAMAPTSMN1; SMN2CCR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352316-B2 | Opioid receptor modulators and products and methods related thereto | EPIODYNE, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210163402-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210147343-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE, INC. | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352316-B2 | Opioid receptor modulators and products and methods related thereto | OPRM1, OPRD1, OPRK1 | LMNA 3394/4885MAPT 2208/4885SMN1; SMN2 3077/4885 |
| US-20210163402-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | OPRM1, OPRD1, OPRK1 | LMNA 3394/4885MAPT 2208/4885SMN1; SMN2 3077/4885 |
| US-20210147343-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | OPRM1, OPRD1, OPRK1 | LMNA 3162/4885MAPT 1862/4885SMN1; SMN2 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.